Chimeric Endolysin Domains for Potent Staphylococcus Lysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing endolysins targeting Staphylococcus species face challenges with low enzyme activity, difficult production in large quantities, and protein stability, limiting their effectiveness in treating infections and maintaining specificity against antibiotic-resistant strains.
Innovation Solution
A novel chimeric endolysin polypeptide with at least 85% sequence identity to SEQ ID NO: 1, featuring enhanced lytic activity and stability, produced using recombinant technology in E. coli, and purified through chromatography, with dialysis against chelating compounds and divalent metal ions to enhance performance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional endolysins are used to target Staphylococcus, then specificity against Staphylococcus is achieved, but enzyme activity is low and protein stability is poor
Solution Approach 1:
The patent merges multiple functional domains into a single chimeric endolysin protein. The endolysin comprises a cell wall binding domain (CBD) that specifically binds to Staphylococcus cell walls and an enzymatically active domain (EAD) that hydrolyzes peptidoglycan. This combination of specific binding and potent enzymatic activity in one protein molecule resolves the contradiction between maintaining specificity and achieving high enzyme activity.
Solution Approach 2:
The endolysin is constructed as a composite protein structure integrating different functional domains with complementary properties. The CBD provides specific recognition and binding to Staphylococcus cell walls, while the EAD provides potent peptidoglycan hydrolysis. This composite structure allows the protein to simultaneously achieve high specificity and high enzymatic power, overcoming the limitations of conventional single-domain endolysins.
2Reliability
If conventional endolysins are used to target Staphylococcus, then specificity is maintained, but production in large quantities is difficult
Solution Approach 1:
The patent employs recombinant DNA technology to create a synthetic copy of the endolysin gene, which is then expressed in host cells (such as E. coli) for mass production. This genetic copying approach allows for large-scale production of the endolysin protein while maintaining the specific sequence and functional properties encoded in the gene, thereby achieving high productivity without sacrificing specificity.
3Power
If conventional endolysins are used to target Staphylococcus, then antimicrobial activity is achieved, but protein stability is poor
Solution Approach 1:
The patent optimizes the structural and sequence parameters of the endolysin protein to enhance its stability. By carefully designing the CBD and EAD domains with appropriate structural features and optimizing their interface, the protein achieves both high antimicrobial activity and improved stability. The chimeric structure allows for parameter optimization that maintains functionality while enhancing robustness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel endolysin demonstrates superior lytic activity against Staphylococcus aureus, achieving a two to three log unit increase in killing compared to benchmark endolysins, while maintaining specificity and minimizing impact on beneficial microflora, thus addressing antibiotic resistance concerns.
Implementation Method 1
Peptidoglycan hydrolases (PGHs) can cleave specific bonds within the peptidoglycan (PG) network of bacteria
Implementation Method 2
Endolysins are highly specific, phage-derived PGHs, active against both drug-sensitive and resistant bacteria
Implementation Method 3
The high specificity of staphylococcal PGHs may be attributed to their CBDs, which regularly feature an SH3b-fold. The structures of staphylococcal endolysin SH3b domains have been solved and display great homology to the bacteriocins lysostaphin (LST) and ALE1, suggesting a common recognition site in the PG.
Data Source
AI summary
The disclosure relates to the field of antibacterial polypeptides, specifically to the field of antibacterial polypeptides having lytic activity for Staphylococcus. Provided herein is a novel chimeric endolysin polypeptide specifically targeting a Staphylococcus cell. Also provided is the use of the chimeric endolysin polypeptide as a disinfectant, as an antimicrobial cosmetic, for detection, such as in a diagnostic application and for medical use, such as for treating an individual suffering from a condition associated with a Staphylococcus infection.